Integra LifeSciences Valuation
| IART Stock | USD 23.00 0.07 0.31% |
At this time, the firm appears to be overvalued. Integra LifeSciences retains a regular Real Value of $18.83 per share. The prevalent price of the firm is $23.0. Our model calculates the value of Integra LifeSciences from evaluating the firm fundamentals such as Return On Equity of -0.0042, return on asset of 0.0302, and Current Valuation of 3.48 B as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Integra LifeSciences' valuation include:
Price Book 1.1628 | Enterprise Value 3.5 B | Enterprise Value Ebitda 18.5399 | Price Sales 1.1341 | Forward PE 9.2081 |
Overvalued
Today
Please note that Integra LifeSciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Integra LifeSciences is based on 3 months time horizon. Increasing Integra LifeSciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Integra LifeSciences' intrinsic value may or may not be the same as its current market price of 23.00, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23.0 | Real 18.83 | Target 46.89 | Hype 23.0 | Naive 20.64 |
The intrinsic value of Integra LifeSciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Integra LifeSciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Integra LifeSciences Holdings helps investors to forecast how Integra stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Integra LifeSciences more accurately as focusing exclusively on Integra LifeSciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Integra LifeSciences' intrinsic value based on its ongoing forecasts of Integra LifeSciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Integra LifeSciences' closest peers.
Integra LifeSciences Cash |
|
Integra Valuation Trend
Integra LifeSciences' real value is important for investors to make better decisions and a more accurate overall view of Integra LifeSciences' financial worth over time. Using both Integra LifeSciences' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Integra Revenue by Product
Integra LifeSciences Total Value Analysis
Integra LifeSciences Holdings is currently projected to have valuation of 3.48 B with market capitalization of 1.77 B, debt of 1.68 B, and cash on hands of 451.52 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Integra LifeSciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.48 B | 1.77 B | 1.68 B | 451.52 M |
Integra LifeSciences Investor Information
About 93.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.16. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integra LifeSciences has Price/Earnings To Growth (PEG) ratio of 0.77. The entity recorded a loss per share of 0.09. The firm had not issued any dividends in recent years. Integra LifeSciences had 2:1 split on the 4th of January 2017. Based on the key indicators related to Integra LifeSciences' liquidity, profitability, solvency, and operating efficiency, Integra LifeSciences Holdings is performing exceptionally good at this time. It has a great probability to report excellent financial results in December.Integra LifeSciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Integra LifeSciences has an asset utilization ratio of 40.76 percent. This implies that the Company is making $0.41 for each dollar of assets. An increasing asset utilization means that Integra LifeSciences Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Integra LifeSciences Ownership Allocation
Integra LifeSciences Holdings has a total of 77.16 Million outstanding shares. The majority of Integra LifeSciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Integra LifeSciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Integra LifeSciences Holdings. Please pay attention to any change in the institutional holdings of Integra LifeSciences as this could imply that something significant has changed or is about to change at the company. On July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Integra LifeSciences's common stock.Integra LifeSciences Profitability Analysis
The company reported the previous year's revenue of 1.54 B. Net Income was 67.74 M with profit before overhead, payroll, taxes, and interest of 982.03 M.About Integra LifeSciences Valuation
The stock valuation mechanism determines Integra LifeSciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Integra LifeSciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Integra LifeSciences. We calculate exposure to Integra LifeSciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Integra LifeSciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 888.4 M | 458 M | |
| Pretax Profit Margin | 0.05 | 0.06 | |
| Operating Profit Margin | 0.07 | 0.08 | |
| Net Profit Margin | 0.04 | 0.05 | |
| Gross Profit Margin | 0.58 | 0.50 |
Integra LifeSciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Integra LifeSciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 80.3 M | |
| Quarterly Earnings Growth Y O Y | -0.601 | |
| Forward Price Earnings | 9.2081 |
Integra LifeSciences Current Valuation Indicators
Integra LifeSciences' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Integra LifeSciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Integra LifeSciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Integra LifeSciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Integra LifeSciences' worth.Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.